T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing

Blood

Volumn 120, Issue 22, 2012, Pages 4334-4342

  Zhou, Qi ^a   Schneider, Irene C ^a   Edes, Inan ^b   Honegger, Annemarie ^c   Bach, Patricia ^a   Schönfeld, Kurt ^d   Schambach, Axel ^e   Wels, Winfried S ^d   Kneissl, Sabrina ^a   Uckert, Wolfgang ^b   Buchholz, Christian J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GRANZYME B; LENTIVIRUS VECTOR; PERFORIN; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84869758434     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412973     Document Type: Article

References (49)

1. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12(5):301-315.
2. Jones S, Peng PD, Yang S, et al. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene Ther. 2009;20(6):630-640.
3. Kieback E, Uckert W. Enhanced T cell receptor gene therapy for cancer. Expert Opin Biol Ther. 2010;10(5):749-762.
4. Yang H, Joo KI, Ziegler L, Wang P. Cell typespecific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res. 2009;26(6):1432-1445.
5. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161-168.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
7. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271.
8. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-129. (Pubitemid 44547756)
9. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-6115. (Pubitemid 44703776)
10. Anliker B, Abel T, Kneissl S, et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods. 2010;7(11):929-935.
11. Münch RC, Muhlebach MD, Schaser T, et al. DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther. 2011;19(4):686-693.
12. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296(1):57-86.
13. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. (Pubitemid 28471781)
14. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther. 2005;16(7):799-810. (Pubitemid 40982329)
15. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol. 2004;78(2):568-575. (Pubitemid 38067578)
16. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther. 2000;2(5):435-445.
17. Schambach A, Bohne J, Chandra S, et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther. 2006;13(2):391-400. (Pubitemid 43056905)
18. Wilde S, Sommermeyer D, Frankenberger B, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009;114(10):2131-2139.
19. Funke S, Maisner A, Muhlebach MD, et al. Targeted cell entry of lentiviral vectors. Mol Ther. 2008;16(8):1427-1436.
20. Liang X, Weigand LU, Schuster IG, et al. A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire. J Immunol. 2010;184(3):1617-1629.
21. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995;55(14):3149-3157.
22. Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ. Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology. 2011;413(2):149-152.
23. Müller T, Uherek C, Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57(3):411-423. (Pubitemid 350295385)
24. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206(4416):347-349. (Pubitemid 10244191)
25. Funke S, Schneider IC, Glaser S, et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 2009;16(5):700-705.
26. Frecha C, Costa C, Negre D, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood. 2008;112(13):4843-4852.
27. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368-8377.
28. Shafer-Weaver KA, Watkins SK, Anderson MJ, et al. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 2009;69(15):6256-6264.
29. Marzo AL, Kinnear BF, Lake RA, et al. Tumorspecific CD4+ T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J Immunol. 2000;165(11):6047-6055.
30. Clement M, Ladell K, Ekeruche-Makinde J, et al. Anti-CD8 antibodies can trigger CD8 T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol. 2011;187(2):654-663.
31. Apte SH, Baz A, Groves P, Kelso A, Kienzle N. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells. Proc Natl Acad Sci U S A. 2008;105(45):17475-17480.
32. Perro M, Tsang J, Xue SA, et al. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther. 2010; 17(6):721-732.
33. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, Trono D, Taylor N, Cosset FL. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 2003;101(6):2167-2174. (Pubitemid 36302054)
34. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004; 2(8):E234.
35. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev. 2010;234(1):18-31.
36. Gao GF, Tormo J, Gerth UC, et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature. 1997; 387(6633):630-634. (Pubitemid 27248771)
37. Sewell AK, Gerth UC, Price DA, et al. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. Nat Med. 1999;5(4):399-404. (Pubitemid 29180577)
38. Hutchinson SL, Wooldridge L, Tafuro S, et al. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem. 2003;278(27):24285-24293. (Pubitemid 37548578)
39. Purbhoo MA, Boulter JM, Price DA, et al. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem. 2001;276(35):32786-32792.
40. Stone JD, Aggen DH, Chervin AS, et al. Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8. J Immunol. 2011;186(9):5193-5200.
41. Xiao Z, Mescher MF, Jameson SC. Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med. 2007;204(11):2667-2677. (Pubitemid 350044790)
42. Park JH, Adoro S, Lucas PJ, et al. 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol. 2007;8(10):1049-1059. (Pubitemid 47430446)
43. Maile R, Siler CA, Kerry SE, Midkiff KE, Collins EJ, Frelinger JA. Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol. 2005; 174(2):619-627. (Pubitemid 40094253)
44. Kienzle N, Buttigieg K, Groves P, Kawula T, Kelso A. A clonal culture system demonstrates that IL-4 induces a subpopulation of noncytolytic T cells with low CD8, perforin, and granzyme expression. J Immunol. 2002;168(4):1672- 1681. (Pubitemid 34135763)
45. Zhu P, Liu J, Bess J Jr, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441(7095):847-852.
46. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16(4):457-472. (Pubitemid 40647143)
47. Thomas S, Xue SA, Cesco-Gaspere M, et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol. 2007;179(9):5803-5810.
48. Almeida JR, Sauce D, Price DA, et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood. 2009;113(25):6351-6360.
49. Varadarajan N, Julg B, Yamanaka YJ, et al. A high-throughput single-cell analysis of human CD8 T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest. 2011;121(11):4322-4331.